

Agenda

All times are in Central European time (CET)

24 November

10.00-10.10	Welcome and introductions	Wanda van der Stel (RIVM)
Session 2 (Due to time zones) NAMs in non-EU Countries Chair Blanca Suarez Merino (NIA)		
10.10-10.30	Development of a New In Vitro Test Method for Evaluating the Immunotoxicity of Inhaled Nanomaterials through Measurement of Activation in Tissue-Resident Alveolar Macrophages	Takao Ashikaga (Section Chief, National Institute of Health Sciences) and Yuki Yamamoto (CEO, HiLung Inc.)
Session 1 Introduction to NAMs Policy, Regulations and Future Direction Chair Wanda van der Stel (RIVM)		
10.30-10.50	NAMs in regulatory assessment	Elise GRIGNARD (Policy analyst, OECD (Organisation for Economic Co-operation and Development))
10.50-11.10	TBC: DG RTD role in the future of NAMs	Fergal Donnelly (DG RTD)
11.10-11.30	TBC: How does ECHA see NAMs	Tomasz Sobanski (ECHA)
11.30-11.40	**Coffee BREAK**	
11.40-12.00	EFSA work on NAMs and phasing out animal testing	Sofia Batista Leite (Pesticide Peer review Unit, European Food Safety Authority (EFSA))x
12.00-12.20	TBC: VAMAS's role in NAMs development	Sam Gnaniah (NPL)
12.20-12.40	TBC: NAMs qualification scheme from NAMs4Nano	Andrea Haase (BfR)
12.40-13.00	ECVAM's perspectives on the acceptance of NAMs for chemical safety assessment	Ingrid Langezaal (Scientific Project Officer, European Commission Joint Research Centre)

13.00-13.20	Validation strategies for regulatory acceptance of NAMs	Kevin Schlüppmann (Validation Project Manager, Pepper)
13.20-13.50	**Lunch**	
Session 3 Part 1: Integrating NAMs into frameworks Chair Sean Kelly (NIA)		
13.50-14.10	TBC: Integration of NAMs in IATAs to stimulate acceptance	Kristie Sullivan (Institute for In Vitro Sciences)
Session 2 NAMs in non-EU Countries Chair Blanca Suarez Merino (NIA)		
14.10-14.30	From Promising Biology to Trusted Safety Assays: Advancing Cardiac and Neural NAMs Towards Regulatory Use	Mike Clements (SVP Scientific Partnerships & Strategy, Axion BioSystems)
14:30-14:50	Integrating New Approach Methodologies (NAMs) for Safe and Sustainable Cosmetic Development	Damaris Cristine Marios Ferreira Pinto (Research Specialist, Boticario Group)
14:50-15.10	TBC: Developing of Absentia Labs Hepatotoxicity AI model as NAM on FDA's iSTAND list	Robert Betancourt (Absentia Labs)
15.10-15.50	Panel discussion on NAMs development throughout the world. What role should Europe play?	All speakers Chair Blanca Suarez Merino (NIA)
15.50	Wrap-up and conclusions	Sean Kelly (NIA)
16.00	Close	

25 November

10.00-10.10	Welcome and introductions	Chair Elisabeth Heunisch (BAuA)
Session 3 Part2: Integrating NAMs into frameworks Chair Sean Kelly (NIA)		
10.10-10.30	TBC: SSbD Hubs and the use of NAMs	Hedwig Braakhuis (TNO)
Session 4 Developing and Using NAMs (Chair Elisabeth Heunisch (BAuA))		
10.30-10.50	TBC: In silico from the Desiderata project	Anastasios (Tassos) Papadiamantis (Entelos)
10.50-11.10	TBC: High content, high throughput imaging assays - towards multi-parameteric NAMs	Jacek Kolanowski (IBCH PAS)
11.10-11.30	In-vitro-learned digital twin: a NAM for chronic lung inflammation	Janez Štrancar (CEO, Infinite d.o.o. / Infinite Biotech)
11.30-11.40	**Coffee Break**	
11.40-12.00	TBC: Transcriptomics in the Desiderata project	Jack Morikka (TAU)

12.00-12.20	TBC: Applied Omics: High-Throughput NAMs for SSbD	Francisco Jose Roig Molina
12.20-12.50	Panel discussion	All speakers Chair: **Elisabeth Heunisch (BAuA))**
12.50	**Lunch Break**	
Session 5 Developing and Using NAMs Part 2 (Chair Alberto Katsumiti, Gaiker)		
13.20-13.40	Beyond the guideline endpoint: what sub-lethal responses add to harmonized testing of advanced materials	Kahina Mehennaoui (Senior R&T Associate, Luxembourg Institute of Science and Technology (LIST))
13.40-14.00	TBC: In silico in the Desiderata project	Santiago Aparicio (UBU)
14.00-14.20	Application of NAM-based in vitro screening model for the neurotoxicity assessment of advanced materials.	Itziar Polanco Garriz (PhD student/researcher at GAIKER Research Centre)
14.20-14.40	TBC: CHIASMA project work on in vitro model validation	Wanda van der Stel (RIVM)
14.40-15.40	Panel discussion	All speakers **Chair Alberto Katsumiti, Gaiker**
15.40	Wrap-up and Summary	Sean Kelly (NIA)
16.00	Meeting close	